Bioengineered cardiac tissue grown from induced pluripotent stem cells has demonstrated encouraging early signs of heart repair in patients with advanced heart failure, according to a first-in-human clinical study published in the New England Journal of Medicine.
For decades, cardiologists have faced a fundamental limitation in the treatment of heart failure: while drugs and devices can slow disease progression, they cannot replace the billions of heart muscle cells lost as the failing heart deteriorates. Now, researchers in Germany have reported early clinical evidence that engineered human heart tissue may begin to address that challenge.
In a phase 1–2 trial known as BioVAT-HF, investigators transplanted laboratory-grown cardiac muscle patches derived from allogeneic induced pluripotent stem cells (iPSCs) onto the hearts of patients with severe heart failure. The interim findings, published in the New England Journal of Medicine, suggest that the experimental therapy can increase heart wall thickness, modestly improve cardiac function, and enhance quality of life, although significant safety challenges remain and larger controlled studies will be needed.
The study represents one of the most advanced attempts yet to achieve true cardiac remuscularization—the restoration of lost heart muscle through regenerative medicine.
A New Approach to a Persistent Problem
Heart failure affects more than 64 million people worldwide and remains one of the leading causes of hospitalization and death. Patients with advanced heart failure and reduced ejection fraction often experience progressive deterioration despite receiving the best available medical therapies.
“The majority of patients are left with medical therapy and palliative care alone,” the investigators wrote.
Heart transplantation and mechanical circulatory support devices remain effective but are available to only a small fraction of eligible patients. The scarcity of donor organs and the complexity of ventricular assist devices leave a substantial unmet need.
The BioVAT approach seeks to directly replace lost myocardium. Researchers led by Dr. Wolfram-Hubertus Zimmermann of the University Medical Center Göttingen developed what they call biologic ventricular assist tissue (BioVAT), consisting of engineered heart muscle created from cardiomyocytes and stromal cells derived from induced pluripotent stem cells.
Unlike traditional cell injections, the therapy delivers organized sheets of contractile tissue that can be surgically attached to damaged regions of the heart.
Each engineered-heart-muscle unit contains approximately 34 million cardiomyocytes and 6 million supporting stromal cells embedded within a collagen scaffold. Multiple units are assembled into a larger patch and sutured onto the epicardial surface of the heart through a minimally invasive thoracotomy procedure.
Testing Cardiac Remuscularization in Humans
The open-label study enrolled patients with symptomatic heart failure and a left ventricular ejection fraction of 35% or less despite guideline-directed therapy.
Twenty patients ultimately received BioVAT transplantation. The trial initially evaluated escalating doses consisting of five, ten, and twenty engineered-heart-muscle units before identifying twenty units as the maximal safe dose. Sixteen patients received this highest dose and formed the primary efficacy cohort.
Participants represented a particularly high-risk population. All had advanced heart failure, had been living with the disease for an average of nearly five years, and were already receiving contemporary medical therapy, including beta-blockers, angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, and implantable defibrillator devices.
Because the transplanted tissue originated from donor-derived stem cells, all patients also received immunosuppressive therapy.
Evidence of Structural Heart Repair
At the prespecified three-month interim analysis, investigators observed measurable changes in cardiac structure and function.
The most striking finding was an increase in thickness of the targeted ventricular wall. Patients treated with the maximal BioVAT dose experienced an average increase of 4.5 millimeters in the treated region of the heart.
Imaging studies suggested that the transplanted tissue successfully engrafted and contributed to thickening of previously damaged myocardial segments.
Researchers also reported an average improvement in left ventricular ejection fraction of 3.9 percentage points. Although modest, such changes can be clinically meaningful in patients with severe systolic dysfunction.
Quality-of-life assessments showed similar trends. Scores on the Kansas City Cardiomyopathy Questionnaire Overall Summary Score improved by an average of 6.7 points, a change generally considered clinically relevant in heart failure research.
Longer-term observations, although limited to smaller numbers of patients, suggested that some benefits may persist. Among eight patients with extended follow-up, ejection fraction increased by an average of nearly seven percentage points over a mean follow-up period of 17 months.
Safety Remains a Major Consideration
As expected for a first-in-human regenerative therapy targeting advanced heart failure, safety findings were complex.
Every patient experienced at least one adverse event, and investigators recorded 196 adverse events overall, including 57 classified as serious.
Three patients died during the study. One died six days after treatment from systemic inflammatory response syndrome and vasoplegia. Another died after severe COVID-19–related cardiopulmonary decompensation. A third died from a type A aortic dissection following a complicated hospitalization marked by recurrent ventricular arrhythmias.
An independent safety review concluded that none of the deaths were directly attributable to the BioVAT transplant itself.
Arrhythmias have long been a concern in cardiac regeneration studies because transplanted cardiomyocytes may potentially disrupt the heart’s electrical conduction system. In BioVAT-HF, three patients experienced episodes of ventricular tachycardia. Detailed electrophysiologic mapping suggested that these events were not directly linked to the transplanted tissue, and all cases were successfully treated with catheter ablation.
No episodes of ventricular fibrillation were reported.
Immunosuppression also introduced challenges. Several patients required adjustments because of declining kidney function, and treatment was discontinued in some cases due to renal disease, implantation of mechanical circulatory support, or cancer diagnosis.
A Milestone for Regenerative Cardiology
The significance of the study extends beyond its immediate clinical results.
Previous regenerative approaches using stem-cell injections have generally failed to demonstrate robust remuscularization. By contrast, BioVAT delivers organized, contractile tissue engineered to survive and integrate with the host myocardium.
The strategy builds upon more than a decade of laboratory and preclinical research. Earlier studies in nonhuman primates demonstrated successful engraftment of engineered heart muscle, while examination of a transplanted human heart removed during subsequent transplantation provided direct evidence that the grafted tissue could survive and form new muscle within the human heart.
Those findings helped convince regulators and investigators that a clinical trial was warranted.
Conceptually, the approach addresses one of the central pathological features of heart failure: the irreversible loss of cardiomyocytes. Investigators estimate that patients with symptomatic heart failure may lose as many as one billion cardiomyocytes over the course of disease progression.
Replacing even a fraction of those cells could alter the natural history of heart failure in ways that current therapies cannot.
Important Questions Remain
Despite the excitement surrounding the results, experts caution that the findings remain preliminary.
The study was small, lacked a control group, and relied largely on surrogate markers rather than hard clinical outcomes such as mortality or hospitalization. Furthermore, the follow-up period remains relatively short, making it impossible to determine whether structural improvements will translate into durable clinical benefits.
Researchers also acknowledge that not all patients may respond equally. The extent of scar tissue, the underlying cause of heart failure, and the ability of transplanted cardiomyocytes to electrically and mechanically integrate with host tissue may all influence outcomes.
A larger phase 3 trial will be required to determine whether BioVAT can reduce hospitalizations, delay transplantation or mechanical circulatory support, and ultimately improve survival.
The Road Ahead
Although many regenerative medicine strategies have struggled to move beyond laboratory success, BioVAT-HF offers some of the strongest clinical evidence to date that engineered human heart tissue can be implanted safely and produce measurable biological effects in patients with advanced heart failure.
The study’s authors conclude that the observed increases in heart-wall thickness, ventricular function, and patient-reported quality of life support continued clinical development of the technology.
Whether stem-cell-derived heart muscle can eventually become a practical alternative to transplantation or mechanical support remains uncertain. Yet for a field that has long pursued the goal of rebuilding damaged hearts, the BioVAT results mark an important step toward making cardiac regeneration a clinical reality rather than a scientific aspiration.
References:
